https://www.selleckchem.com/products/DMXAA(ASA404).html OBJECTIVE The aim of this study was to investigate the level of cyclin-dependent kinase inhibitor 3 (CDKN3) in colorectal cancer (CRC), to explore the underlying mechanism of CDKN3 in modulating cisplatin resistance and promoting the malignant progression of CRC. PATIENTS AND METHODS 43 pairs of CRC tissues and para-cancerous tissues were collected from CRC patients. CDKN3 expression was detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The relationship between CDKN3 expression and the prognosis of CRC patients was analyzed. Meanwhile, qRT-PCR was performed to verify CDKN3 level in CRC cell lines. Next, CDKN3 knockdown model was constructed in CRC cisplatin-resistant cell lines. The influence of CDKN3 on the biological function of CRC cells was analyzed by Cell Counting Kit-8 (CCK-8) and plate cloning assays. Furthermore, the mechanism of its regulation of TIPE1 affecting cisplatin resistance to CRC was explored. RESULTS QRT-PCR results showed that CDKN3 level in CRC tissues was remarkabSIONS CDKN3 was highly expressed in CRC, which might be closely correlated with poor prognosis of CRC patients. In addition, CDKN3 regulated cisplatin resistance to CRC by modulating TIPE1, thereby promoting the proliferation of CRC.OBJECTIVE Currently, the therapeutic effect on patients with liver cancer is associated with disease development. Meanwhile, the efficacy in patients with advanced liver cancer is far from satisfactory. Therefore, the aim of this study was to explore the association of disease condition with changes in liver function indexes, intestinal flora, and plasma endotoxin (ET) and vascular endothelial growth factor (VEGF) levels in patients with liver cancer. PATIENTS AND METHODS A total of 300 patients with primary liver cancer in our hospital were enrolled in this study. All patients were divided into three groups, including early liver cancer group, middle liver cancer group, and adv